ADO 12
Alternative Names: ADO-12; AdoShell® Islets; Cell therapy for diabetes - Adocia; Pancreatic beta cell therapy - AdociaLatest Information Update: 28 Jul 2025
At a glance
- Originator Adocia
- Class Antihyperglycaemics; Cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in France (Parenteral)
- 24 Jun 2025 Adocia plans to submit a clinical trial application for AdoShell® with human islets in 2025
- 24 Jun 2025 Pharmacodynamics data from a preclinical trial in Type 1 diabetes mellitus released by Adocia